Dr. Umar Raza
Assistant Professor
Biological Sciences

Phone: +92 (51) 9270677, +92 (51) 5124950
Email: umer.raza@numspak.edu.pk, umarraza698@gmail.com

Specialization:
Cancer Molecular Biology

Education:
MS leading to PhD in Molecular Biology and Genetics (2012 - 2017), Bilkent University, Ankara, Turkey.
B.Sc. (Hons) Agriculture (2006 - 2010), University of Agriculture, Faisalabad, Pakistan.

Experience:

Assistant Professor (2018 – To date), National University of Medical Sciences, Rawalpindi, Pakistan.

Research Interests:
Cancer therapy resistance, Metastasis, Signaling pathways, Non-coding RNAs, miRNA-mRNA regulatory networks

Publications:

1. **Systems biology based meth-miRNA–mRNA regulatory network identifies metabolic imbalance and hyperactive cell cycle signaling involved in hepatocellular carcinoma onset and progression**. Zahid KR, Su M, Khan ARR, Han S, Deming G, **Raza U***. Cancer Cell International. April, 2019.
2. **Novel tumor suppressor SPRYD4 inhibits tumor progression in hepatocellular carcinoma by inducing apoptotic cell death**. Zahid KR, Han S, Zhou F, **Raza U***. Cellular Oncology. September, 2018.
3. **Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer**. Saatci O, Borgoni S, Akbulut O, Durmus S, **Raza U**, Eyupoglu E, Alkan C, Akyol A, Kutuk O, Wiemann S, Sahin O. Oncogene. February, 2018.
4. **Re-activation of cAMP pathway by PDE4D inhibition represents a novel druggable axis for overcoming tamoxifen resistance in ER-positive breast cancer**. Mishra RR, Belder N, Ansari S, Kayhan M, Bal H, **Raza U**, Ersan PG, Tokat

UM, Eyupoglu E, Saatci O, Jandaghi P, Wiemann S, Uner A, Cekic C, Riazalhosseini Y, Sahin O. Clinical Cancer Research. January, 2018.

5. **Polyol pathway links glucose metabolism to the aggressiveness of cancer cells**. Schwab A, Siddiqui A, Vazakidou ME, Napoli F, Böttcher M, Menchicchi B, **Raza U**, Saatci O, Krebs AM, Ferrazzi F, Rapa I, Wilde KD, Waldner MJ, Ekici AB, Rasheed SAK, Mougiakakos D, Oefner PJ, Sahin O, Volante M, Greten FR, Brabletz T, Ceppi P. Cancer Research. January, 2018.
6. **miR-564 acts as a dual inhibitor of PI3K and MAPK signaling networks and inhibits proliferation and invasion in breast cancer**. Mutlu M, Saatci O, Ansari SA, Yurdusev E, Shehwana H, Konu O, **Raza U**, Sahin O. Scientific Reports. September, 2016.
7. **The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer**. **Raza U**, Saatci O, Uhlmann S, Ansari SA, Eyupoglu E, Yurdusev E, Mutlu M, Ersan PG, Altundag MK, Zhang JD, Dogan HT, Guler G, Sahin O. Oncotarget. July, 2016.
8. **miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance**. Mutlu M, **Raza U**, Saatci O, Eyupoglu E, Yurdusev E, Sahin O. J Mol Med. June, 2016.
9. **MicroRNAs: master regulators of drug resistance, stemness, and metastasis**. **Raza U**, Zhang JD, Sahin O. J Mol Med. April, 2014.